We have previously reported an association between the activator protein-2b (AP-2b) transcription factor gene and type 2 diabetes. This gene is preferentially expressed in adipose tissue, and subjects with a disease-susceptible allele of AP-2b showed stronger AP-2b expression in adipose tissue than those without the susceptible allele. Furthermore, overexpression of AP-2b led to lipid accumulation and induced insulin resistance in 3T3-L1 adipocytes. Result: We found that overexpression of AP-2b in 3T3-L1 adipocytes decreased the promoter activity of leptin, and subsequently decreased both messenger RNA (mRNA) and protein expression and secretion. Furthermore, knockdown of endogenous AP-2b by RNA-interference increased mRNA and protein expression of leptin. Electrophoretic mobility shift and chromatin immunoprecipitation assays revealed specific binding of AP-2b to leptin promoter regions in vitro and in vivo. In addition, site-directed mutagenesis of the AP-2-binding site located between position þ 34 and þ 42 relative to the transcription start site abolished the inhibitory effect of AP-2b. Our results clearly showed that AP-2b directly inhibited insulin-sensitizing hormone leptin expression by binding to its promoter. Conclusion: AP-2b modulated the expression of leptin through direct interaction with its promoter region.
Introduction
We recently identified the human activator protein-2b (AP-2b) transcription factor gene (TFAP2B) located on chromosome 6p12 as a susceptibility gene for type 2 diabetes in a genome-wide association study. 1 Several variations in the TFAP2B gene were significantly associated with obese type 2 diabetes in Japanese and British individuals. 1 Furthermore, a polymorphism in the first intron of TFAP2B directly affects transcriptional activity of the gene, and subjects with the disease-susceptible allele have greater expression of AP-2b in their adipose tissue than those without the susceptible allele. 2 We have also reported that mouse AP-2b (Tcfap2b) was preferentially expressed in adipose tissue and that its expression increased during adipocyte differentiation in 3T3-L1 adipocytes. 1 In addition, we observed that overexpression of AP-2b led to lipid accumulation by enhancing glucose transport, thereby inducing insulin resistance in 3T3-L1 adipocytes. 3 Moreover, we reported that AP-2b could inhibit transcriptional activity of the adiponectin gene by binding to the adiponectin promoter and could increase the expression of interleukin-6 gene and monocyte chemoattractant protein-1 (MCP-1) gene in 3T3-L1 adipocytes. 4, 5 These phenomena are considered to have crucial roles in the pathogenesis of obesityrelated diseases, such as metabolic syndrome and type 2 diabetes. Supporting our findings, it has been reported that TFAP2B is associated with insulin resistance and adiposity in healthy adolescents. 6 Furthermore, a recent meta-analysis of 16
genome-wide association studies (N ¼ 38 580) and follow-up studies in a maximum of 70 689 individuals showed a strong association between central adiposity and fat distribution with TFAP2B locus. 7 These lines of evidence suggest that TFAP2B has important roles in the pathogenesis of metabolic syndrome and type 2 diabetes, and acts through dysregulation of adipocyte function and those polymorphisms in TFAP2B that affect gene expression, thus conferring disease susceptibility. Adipose tissue is an important source of metabolically active secretory factors, including free fatty acids, leptin, tumor necrosis factor-a, interleukin-6, MCP-1, plasminogen activator inhibitor-1, resistin, visfatin and adiponectin. 8, 9 Especially, leptin has a key role in regulating food intake and energy expenditure, and participates in increasing glucose metabolism. 10, 11 Leptin deficiency causes obesity, insulin resistance and diabetes in mice and humans. [12] [13] [14] [15] Leptin replacement reverses insulin resistance and diabetes mellitus in mouse and human leptin-deficiency models. [16] [17] [18] In addition, leptin has beneficial effects on glycemic and lipid control in a mouse model for type 2 diabetes. 19 These lines of evidence revealed that decreased leptin actions caused insulin resistance. We reported that AP-2b regulated adipokine gene expression, such as that of adiponectin, interleukin-6 and MCP-1 in 3T3-L1 adipocytes. However, the role of AP-2b in leptin expression has not been investigated yet; we therefore hypothesized that AP-2b may regulate leptin gene expression.
In this study, we observed that the overexpression of AP-2b in 3T3-L1 adipocytes decreased the expression and secretion of leptin, and knockdown of AP-2b resulted in opposite effects. We also observed that AP-2b directly downregulated leptin gene expression by binding to its gene promoter. Furthermore, we have identified an element that was responsible for AP-2b-mediated leptin gene regulation. We concluded that AP-2b might modulate the expression of leptin through a direct interaction with its promoter region.
Materials and methods

Materials
Human insulin was kindly provided by Eli Lilly (Indianapolis, IN, USA). Anti-AP-2b antibody (H-87), AP-2 consensus oligonucleotide (sc-2513) and horseradish peroxidase-linked antimouse, anti-rabbit and anti-goat antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). An anti-leptin antibody was purchased from Affinity Bioreagents (Golden, CO, USA). The pGL3-Basic luciferase vector and pRL-CMV vector were purchased from Promega (Madison, WI, USA). Dulbecco's modified Eagle's medium and fetal calf serum were obtained from Life Technologies (Grand Island, NY, USA). All radioisotopes were obtained from PerkinElmer Japan (Yokohama, Japan). BioMax MR film was obtained from Eastman Kodak (Rochester, NY, USA). All other reagents and chemicals were from standard suppliers.
Cell culture
The 3T3-L1 cells, provided by Dr JM Olefsky (University of California, San Diego, CA, USA), were cultured and differentiated into adipocytes as previously described. 20 Before each experiment, adipocytes were trypsinized and reseeded in appropriate culture dishes. The adenoviral E1A-transformed human embryonic kidney cell line, HEK-293 cells, was cultured as previously described.
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Preparation of recombinant adenovirus Adenovirus 5-derived adenovirus vector encoding the human AP-2b gene (Adenovirus 5-AP-2b) was generated as previously described. 3 Adenovirus encoding the LacZ gene (Adenovirus 5-LacZ), as previously described, 22, 23 was used as the control.
Preparation of expression plasmid vectors
Plasmid vectors encoding the mouse AP-2b gene (pcDNA3.1/ AP-2b) and mutant AP-2b that lacked DNA-binding ability (pcDNA3.1/AP-2b R225C) were generated as previously described.
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Infection At 10 days after induction of differentiation, 3T3-L1 adipocytes were infected with adenoviruses at the indicated multiplicity of infection for 24 h. Infected cells were incubated for 48 h at 37 1C in an atmosphere of 10% CO 2 in Dulbecco's modified Eagle's medium with 22.5 mM glucose and 2% heat-inactivated fetal calf serum, followed by serum starvation as required for the assay.
Transfection study
The 3T3-L1 adipocyte transfection was performed using the Amaxa Nucleofector technology (Amaxa, Cologne, Germany), as previously described. 3 Briefly, on day 5 after induction of differentiation, the cell suspension was mixed with 5 mg of several kinds of vectors, such as luciferase reporter vector, pRL-CMV and various expression vectors, and electroporated using the program U-28. After transfection, cells were immediately transferred to 1 ml growth medium and cultured for reporter assays, quantitative RT-PCR and western blotting.
Nuclear extraction
Nuclear extracts were prepared as previously described. 24 Briefly, 3T3-L1 adipocytes were rinsed twice with phosphatebuffered saline, and then lightly trypsinized and pelleted by centrifugation at 650 g for 5 min. The pellet was washed twice with phosphate-buffered saline, suspended in lysis buffer A (10 mM Tris-HCl (pH 7.5), 1.5 mM MgCl 2 , 10 mM KCl, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 2 mM sodium vanadate (Na 3 VO 4 ), 2 mM leupeptin, 1 mM aprotinin and 1 mM pepstatin). The cell suspension was homogenized and nuclei were pelleted by centrifugation at 8000 g for 5 min. 
Measurement of luciferase reporter gene activity
The luciferase reporter plasmid for the mouse leptin promoter expression (pGL3/leptin promoter luc) was generated by excising the promoter fragment (À793/ þ 61) from the genomic clone of leptin and inserting it into the SacI and MluI sites of the pGL3-Basic luciferase vector. A mutant leptin promoter vector was generated using a QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Putative AP-2-binding sites in the proximal promoter region of the mouse leptin gene were mutated using the oligonucleotides in the in vitro mutagenesis reaction. The primer for putative AP-2-binding sites for candidate #1 was 5 0 -CCC TTGCCACCTAACCCTGAGACTGGTCCAGAGC-3 0 ; for candidate #2: 5 0 -CCACTGTTGCTGAACCGCTGAGTGGGGCGGG AG-3 0 ; and for candidate #3: 5 0 -CTGCAAGGTAAGGACCG GAACGCGCTACTTTCTCCTC-3 0 ; and the complementary sequence of each primer. After mutagenesis, we confirmed the sequence of all mutated vectors. Luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega), according to the manufacturer's instructions. Luciferase activity values for pRL-CMV (Promega) were measured for normalization.
Electrophoretic mobility shift assay Electrophoretic mobility shift assay was performed using radio-labeled double-strand oligonucleotides, as described previously. 24 Oligonucleotide sequences of putative AP-2-binding sites, candidates #1, #2 and #3 were 5 0 -CTTGCCAC CTGCCCCTGGGACTGGTCCA-3 0 ; 5 0 -CACTGTTGCTGGCCC GCTGGGTGGGGCG-3 0 ; and, 5 0 -TGCAAGGTAAGGCCCGGG GCGCGCTACT-3, respectively. The protein-DNA binding reaction was performed at room temperature for 30 min, and the resultant complexes were resolved on 4% polyacrylamide gels. Competition and supershift assays were performed with a threefold molar excess of unlabeled oligonucleotide or 2 mg of anti-AP-2b antibody (H-87X), respectively.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay protocol described by Latasa et al. 25 was used with some modifications. Briefly, B1 Â 10 6 differentiated 3T3-L1 adipocytes were cross-linked for 10 min by adding formaldehyde directly to the tissue culture medium at a final concentration of 1%. Cross-linking was stopped by the addition of glycine at a final concentration of 125 mM. Cross-linked cells were washed twice with phosphatebuffered saline and scraped. Nuclei were isolated as a nuclear extraction and resuspended in SDS lysis buffer. The chromatin solution was sonicated for 10 s pulses at maximum power. After centrifugation, the supernatant was divided into aliquots for a 10-fold dilution in ChIP dilution buffer and was precleared with protein G-agarose containing salmon sperm DNA for 1 h. Antibodies against the indicated target nuclear proteins were added and incubated for 18 h at 4 1C, followed by incubation with protein G-agarose for 3 h. Precipitates were washed and chromatin complexes were eluted. After reversal of the cross-linking, DNA was purified and 5 mg of input control or ChIP samples were used as a template for PCR using the primer sets for regions containing the candidate AP-2-responsive elements. Primer sequences used for ChIP assay were 5 0 -TTATAAGAGGGGCAGGCA-3 0 and 5 0 -CTGGATGGGGTGCTATTA-3 0 .
Transfection of short hairpin RNAs (shRNAs)
The vector-based shRNA construct against AP-2b and 4-basemutated scrambled negative control were purchased from AP-2b regulates leptin gene expression T Fuke et al Hokkaido System Science (Sapporo, Hokkaido, Japan), and were used as reported previously. 4, 5 We used a mouse U6
promoter-based piGENE-mU6 vector for RNA intereferncemediated knockdown. Target sequences for shRNAs against AP-2b and scrambled control were as follows: AP-2b: 5 0 -CTAC TCAGTTCAACTTCAAAGTACA-3 0 ; scrambled control: 5 0 -CTA CTCAGCCCAACGGCAAAGTACA-3 0 (the scrambled bases are underlined).
Statistical analysis
All values are expressed as mean±s.e.m., unless otherwise stated. Scheffe's multiple comparison test was used to determine the significance of any differences between more than three groups. A P-value less than 0.05 was considered significant.
Results
Overexpression of AP-2b inhibits the gene expression of leptin Adipocyte hypertrophy has been proposed to be the primary cause of dysregulation of expression and secretion of adipokines in obesity, leading to metabolic syndrome and type 2 diabetes. 26 We previously reported that overexpression of AP-2b led to lipid accumulation through enhanced glucose transport in 3T3-L1 adipocytes. 3 We therefore sought to evaluate the expression of adipokine genes under the same conditions. The AP-2b gene was overexpressed in cultured 3T3-L1 adipocytes with adenoviral vector 10 days after differentiation, and the messenger RNA (mRNA) expression of leptin was measured by quantitative RT-PCR at day 14. As shown in Figure 1a , mRNA expression of the leptin gene was inhibited by 56% in AP-2b overexpressing cells. Consistent with these findings, leptin secretion in the culture media was inhibited by 39% in cells overexpressing AP-2b (Figure 1b) . We also confirmed decreased leptin expression in whole cells by AP-2b overexpression in 3T3-L1 adipocytes using western blotting, showing that overexpression of AP-2b markedly reduced protein expression of leptin (Figure 1c ).
Endogenous AP-2b knockdown by shRNA increases expression of leptin To evaluate the physiological role of AP-2b on leptin expression, we knocked down endogenous AP-2b in 3T3-L1 adipocytes by RNA-mediated interference. At 48 h after electroporation of shRNA constructs, mRNA and protein expression of AP-2b was decreased by 72 and 37%, respectively, in AP-2b shRNA-transfected cells compared with scrambled control shRNA-transfected cells (Figures 2a  and b) . In this condition, knockdown of AP-2b significantly increased mRNA and protein expression of leptin (Figures 2a  and b) , whereas increased adiponectin levels and decreased MCP-1 mRNA levels were fully consistent with our previous results (data not shown). 4, 5 These results indicate that endogenous AP-2b negatively regulates leptin expression physiologically.
Overexpression of AP-2b inhibits leptin promoter activity
To explore the possibility that AP-2b directly modulates leptin gene expression, we tested the effect of AP-2b overexpression on transcriptional activities of leptin using luciferase reporter assays. As shown in Figure 3 , overexpression of AP-2b inhibited leptin promoter activity in a dosedependent manner.
DNA binding activity of AP-2b is required for its inhibitory effect on the leptin promoter To determine whether the effect of AP-2b on leptin promoter activity is mediated through its role as a transcription factor, we prepared a mutant AP-2b that lacked the ability to bind to DNA. Mutation of arginine at 225 to cysteine in the DNA-binding domain of AP-2b (R225C) has been reported to 
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abolish DNA-binding ability. 27, 28 We transiently expressed either wild-type or mutant (R225C) AP-2b in 3T3-L1 adipocytes and then measured leptin promoter activity. Although expression levels of both types of AP-2b were similar (Figure 4a ), only wild type had decreased leptin reporter activity (Figure 4b ). These results suggest that the DNAbinding activity of AP-2b is required for its inhibitory effect on leptin promoter activity.
Identification of AP-2b responsive element in leptin promoter
The AP-2 transcription factor family consists of five members: AP-2a, AP-2b, AP-2g, AP-2d and AP-2e. Although each member is encoded by a separate gene, all recognize the same consensus sequence (such as 5 0 -GCCN 3 GGG/C-3 0 ) through the basic domain that lies in the N-terminal of the dimerization motif. [29] [30] [31] [32] [33] As shown in a schematic representation of transcription factor-binding sites (Figure 5a ), we observed that the mouse leptin promoter has three putative AP-2-binding sites (À555 to À547, candidate #1; À110 to À101, candidate #2; and þ 34 to þ 42, candidate #3; Figure 5a ). To identify the exact AP-2-binding sites on the leptin promoter, we point-mutated each putative AP-2-binding site in the leptin promoter region (Figure 5a ; box). When we mutated the candidate #3 site, the inhibitory effect of AP-2b was abolished, but mutants of the candidate #1 or #2 sites had similar effect as wild type on the reporter activity (Figure 5b ). These data suggest that the candidate #3 site is the most important element for AP-2b-mediated leptin gene regulation.
Identification of a crucial element responsible for AP-2b-mediated leptin gene regulation
To further clarify the crucial AP-2b-binding element on the leptin promoter, we performed electro mobility shift assays using nuclear extracts from AP-2b-overexpressing 3T3-L1 adipocytes. The oligonucleotide probe corresponding to candidate #3, which was highly conserved between mice and humans (Figure 6a ), successfully formed a complex with nuclear proteins from AP-2b-overexpressing cells (Figure 6b AP-2b regulates leptin gene expression T Fuke et al candidate #3 (Figure 6b, lanes 8) . The oligonucleotide probe corresponding to candidate #1 and #2 also formed complexes (Figure 6b ; lanes 1 and 3), but these complexes had weaker signals compared with a complex formed by the probe corresponding to candidate #3. To further confirm the specificity of candidate #3, we generated a mutant oligonucleotide probe of candidate #3. We point-mutated C to A at the þ 35 position and GG to AA at the þ 40/ þ 41 position. These replacements totally abolished complex formation (Figure 6b ; lane 9). Taken together with the result on point mutations in the leptin promoter region, these data suggest that the candidate #3 site ( þ 34 to þ 42) is the AP-2b-binding site.
AP-2b binds to the leptin promoter region in vivo
To evaluate the binding of transcriptional factor AP-2b to the leptin promoter region, we performed ChIP assays using the AP-2b antibody. The DNA encompassing the region containing the AP-2b-binding site candidate #3 was amplified by PCR from chromatin-immunoprecipitated with antibodies against AP-2b. The DNA binding of AP-2b was observed in an endogenous condition in which control LacZ was overexpressed (Figure 6c ; left). Furthermore, DNA binding of AP-2b increased in an AP-2b dose-dependent manner (Figure 6c ; middle and right). These results further suggest that AP-2b binds to candidate #3 of the leptin gene promoter, not only in vitro but also in vivo.
Discussion
We proposed previously that the gene encoding transcription factor AP-2b is a candidate gene that causes metabolic syndrome and type 2 diabetes through the induction of adipocyte dysfunction based on our findings, [1] [2] [3] which are supported by recent meta-analysis of genome-wide association studies 7 and the report that TFAP2B is associated with insulin resistance and adiposity in healthy adolescents. 6 In addition, AP-2b seems to downregulate anti-inflammatory molecules, such as adiponectin, 4 and upregulate pro-inflam- 
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and subsequently promotes inflammation and dysfunction of adipocytes. Adipocyte dysfunction is now recognized as an important metabolic pathology related to insulin resistance, type 2 diabetes and cardiovascular diseases. 34 These lines of data suggest that AP-2b has a significant role in adipocyte dysfunction.
In this study, we observed that AP-2b in 3T3-L1 adipocytes decreased the expression and secretion of leptin. Although the functional regulation of leptin is incompletely understood, here we used three distinct approaches to test whether leptin expression is directly regulated by AP-2b. First, we showed reduced expression and secretion of leptin by overexpression of AP-2b. Second, we used a luciferase reporter activity assay to clearly demonstrate that AP-2b inhibited leptin promoter activity. Third, we also observed that AP-2b directly downregulated leptin gene expression by binding to its gene promoter in electrophoretic mobility shift assay and ChIP assays. Furthermore, we have identified an element responsible for AP-2b-mediated leptin gene regulation. Interestingly, the specific AP-2b-binding site candidate #3 in the promoter region of the leptin gene identified in this study was highly conserved between mice and humans (Figure 6a ), indicating that this promoter region of leptin is important for its regulation. Moreover, we used shRNA knockdown to directly demonstrate that endogenous AP-2b is a negative regulator of leptin. It has been reported that several transcriptional factors regulate gene expression of leptin. For example, peroxisome proliferator-activated receptor-g downregulates the leptin gene. 35, 36 However, a CCAAT/enhancer-binding protein (C/EBP) and specificity protein 1 (Sp1) upregulate the leptin gene. 37 We investigated the interaction of these transcriptional factors with AP-2b. However, we did not observe any interaction of these factors with AP-2b. From these results, we conclude that AP-2b modulates the expression of leptin through a direct interaction with its promoter region in vivo and in vitro.
Leptin deficiency causes insulin resistance and diabetes in animals and humans. 14, 15 The phenomenon is explained by decreased fatty acid b-oxidation mediated by AMP-activated protein kinase in skeletal muscle and liver. [38] [39] [40] In addition, Wang et al. 41 showed that leptin could decrease fat content by stimulating a new form of lipolysis. This finding was confirmed by other studies demonstrating that adenovirusinduced hyperleptinemia caused shrinking and fat loss of adipocytes by activated AMP-activated protein kinase in adipocytes. [42] [43] [44] Thus, adipocyte hypertrophy led to an augment of leptin secretion, but as a result, increased secretion of leptin inhibited further expansion of adipocytes. These reports support the idea that leptin is an inhibitory adipocyte hypertrophy hormone and a potentiator of insulin action. In this study, we confirmed a reduction of leptin by AP-2b at several levels, including protein, mRNA, promoter activity and direct binding. AP-2b, which increased with adipocyte hypertrophy, downregulates leptin expression, consequently the inhibitory effect of leptin against adipocyte hypertrophy decreases and adipocytes become enlarged. It is possible that insulin resistance induced by adipocyte hypertrophy is, at least in part, due to reduced leptin expression mediated by AP-2b in 3T3-L1 adipocytes. In general, obesity and adipocyte hypertrophy result in decreased adiponectin expression and increased leptin expression, but AP-2b decreased both adiponectin and leptin expressions in our study using 3T3-L1 adipocytes. The reason for this discrepancy is unknown. Our in vitro adipocyte model system might cause different results. However, De Vos et al. 45 reported that administration of the thiazolidinedione increased adipose tissue weight while reducing leptin mRNA level in rats. They also showed that treatment with peroxisome proliferator-activated receptor-g agonists, which 
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T Fuke et al induced adipocyte differentiation and increased adipose tissue mass, reduced leptin mRNA level in 3T3-L1 adipocytes. This result is consistent with our results in 3T3-L1 adipocytes. Alternatively, there are some reports that suggest the possibility that another regulator involved in leptin expression exists in human obesity states. The heterozygous relatives of leptin-deficient patients were reported to have higher prevalence of obesity than that seen in a control population. 46 Although serum leptin concentrations correlate positively with fat mass, there is considerable interindividual and interethnicity variation at any particular fat mass. 47 Furthermore, in some obese individuals leptin is inappropriately low. 48 In fact, in our experiment with biopsy samples of human fat tissue, we confirmed a negative correlation between mRNA expression of leptin and AP-2b in subcutaneous and visceral fat tissue. 20 Further investigation awaits the characterization of additional mechanisms of action of leptin, including these discrepancies in both health and disease, particularly in obesity.
In conclusion, we found that AP-2b downregulated transcriptional activity of the leptin gene through its specific binding to the promoter region in 3T3-L1 adipocytes and identified the AP-2b binding site in the promoter region of the leptin gene. On the basis of these findings, we conclude that the AP-2b transcriptional factor is a candidate gene responsible for the dysfunction of adipocytes, leading to insulin resistance, metabolic syndrome and type 2 diabetes.
